Form 4: VYNE Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
David Domzalski, PRESIDENT AND CEO and a Director of VYNE Therapeutics Inc., reported a transaction in 79,391 shares of common stock on July 23, 2026.
Summary
- Tax/exercise-price withholding: disposed of 79,391 Common Stock at $0.90 ($71,261) on July 23, 2026; holds 347,174 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Domzalski — Director, Officer (PRESIDENT AND CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-23 | Tax/exercise-price withholding | Common Stock | 79,391 | $1 | $71.3K | 347,174 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-23 | Tax/exercise-price withholding (79,391 shares) |
Keywords
insider transaction, Form 4, VYNE, VYNE Therapeutics Inc., neutral, David Domzalski
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.